In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on RedHill Biopharma (RDHL – Research Report), with a price target of $36. The company’s shares closed on Friday at $7.06.
“We are maintaining our Buy rating on RedHill and our 12-month price target of $36.00 per ADS based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 14%; and 2) price/earnings multiple analysis applying a 15x multiple to our 2025 estimated earnings also discounted at 14%. 1) commercial; 2) regulatory; 3) clinical; 4) partnership; 5) financial; and 6) intellectual property.”
According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.8% and a 30.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Collplant Holdings Ltd.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for RedHill Biopharma with a $22 average price target, which is a 211.6% upside from current levels. In a report issued on December 31, WBB Securities also initiated coverage with a Buy rating on the stock with a $9 price target.
The company has a one-year high of $11.49 and a one-year low of $4.40. Currently, RedHill Biopharma has an average volume of 121.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill’s pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs.